Efficacy of Dronabinol for Acute Pain Management in Adults with Traumatic Injury: Study Protocol of A Randomized Controlled Trial

Claire Swartwood, Kristin Salottolo, Robert Madayag, David Bar-Or, Claire Swartwood, Kristin Salottolo, Robert Madayag, David Bar-Or

Abstract

Delta-9-tetrahydrocannabinol (Δ9-THC) and other cannabinoids present in cannabis (marijuana) have been shown to affect the normal inhibitory pathways that influence nociception in humans. The potential benefits of cannabinoids as an analgesic are likely greatest in hyperalgesic and inflammatory states, suggesting a role as a therapeutic agent for treating acute pain following injury. Dronabinol is a licensed form of Δ9-THC. The primary objective of this single center randomized controlled trial is to evaluate the efficacy of adjunctive dronabinol versus control (systemic analgesics only, no dronabinol) for reducing opioid consumption in adults with traumatic injury. Study inclusion is based on high baseline utilization of opioids ≥50 morphine equivalents (mg) within 24 h of admission for adults aged 18-65 years with traumatic injury. There is a 48-hour screening period followed by a 48-hour treatment period after randomization. A total of 122 patients will be randomized 1:1 across 2 study arms: adjunctive dronabinol versus control (standard of care using systemic analgesics, no adjunctive dronabinol). Patients randomized to the dronabinol arm should receive their first dose within 12 h of randomization, with a dose range of 5 mg up to 30 mg daily in divided doses, in addition to systemic analgesics as needed for pain. The primary efficacy endpoint is a change in opioid consumption (morphine equivalents), assessed post-randomization (48 h after randomization) minus pre-randomization (24 h prior to randomization). This is the first randomized trial to investigate whether adjunctive dronabinol is effective in reducing opioid consumption in acute pain management of traumatic injury. Trial Registration: ClinicalTrials.gov Identifier: NCT03928015.

Keywords: Delta-9-tetrahydrocannabinol; dronabinol; marijuana; opioids; randomized controlled trial; traumatic injury.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Subject Disposition.

References

    1. Pertwee R.G. Cannabinoid pharmacology: The first 66 years. Br. J. Pharmacol. 2006;147(Suppl. 1):S163–S171. doi: 10.1038/sj.bjp.0706406.
    1. National Academies of Sciences Engineering, and Medicine . The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. The National Academies Press; Washington, DC, USA: 2017.
    1. Koppel B.S., Brust J.C., Fife T., Bronstein J., Youssof S., Gronseth G., Gloss D. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82:1556–1563. doi: 10.1212/WNL.0000000000000363.
    1. Whiting P.F., Wolff R.F., Deshpande S., Di Nisio M., Duffy S., Hernandez A.V., Keurentjes J.C., Lang S., Misso K., Ryder S., et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313:2456–2473. doi: 10.1001/jama.2015.6358.
    1. Stevens A.J., Higgins M.D. A systematic review of the analgesic efficacy of cannabinoid medications in the management of acute pain. Acta Anaesthesiol. Scand. 2017;61:268–280. doi: 10.1111/aas.12851.
    1. Iversen L., Chapman V. Cannabinoids: A real prospect for pain relief? Curr. Opin. Pharmacol. 2002;2:50–55. doi: 10.1016/S1471-4892(01)00120-5.
    1. Cichewicz D.L., Martin Z.L., Smith F.L., Welch S.P. Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: Dose-response analysis and receptor identification. J. Pharmacol. Exp. Ther. 1999;289:859–867.
    1. Cichewicz D.L., McCarthy E.A. Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration. J. Pharmacol. Exp. Ther. 2003;304:1010–1015. doi: 10.1124/jpet.102.045575.
    1. Cichewicz D.L., Welch S.P. Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 2003;305:812–817. doi: 10.1124/jpet.102.046870.
    1. Schneider-Smith E., Salottolo K., Swartwood C., Melvin C., Madayag R., Bar-Or D. A Matched Pilot Study Examining Cannabis-Based Dronabinol for Acute Pain Following Traumatic Injury. Trauma Surg. Acute Care Open. 2020;0:e000391. doi: 10.1136/tsaco-2019-000391.
    1. National Center for Injury Prevention and Control . CDC Compilation of Benzodiazepines mr, Stimulants, Zolpidem, and Opioid Analgesics with Oral Morphine Milligram Equivalent Conversion Factors. Centers for Disease Control and Prevention; Atlanta, GA, USA: 2018. [(accessed on 18 December 2017)]. 2018 version. Available online: .
    1. Salottolo K., Peck L., Tanner A., Carrick M.M., Madayag R., McGuire E., Bar-Or D. The grass is not always greener: A multi-institutional pilot study of marijuana use and acute pain management following traumatic injury. Patient Saf. Surg. 2018 doi: 10.1186/s13037-018-0163-3. in press.
    1. Cowperthwaite M.C., Burnett M.G. Treatment course and outcomes following drug and alcohol-related traumatic injuries. J. Trauma Manag. Outcomes. 2011;5:3. doi: 10.1186/1752-2897-5-3.
    1. Rivara F.P., Jurkovich G.J., Gurney J.G., Seguin D., Fligner C.L., Ries R., Raisys V.A., Copass M. The magnitude of acute and chronic alcohol abuse in trauma patients. Arch. Surg. 1993;128:907–912. doi: 10.1001/archsurg.1993.01420200081015.
    1. Chung C., Salottolo K., Tanner A., 2nd, Carrick M.M., Madayag R., Berg G., Lieser M., Bar-Or D. The impact of recreational marijuana commercialization on traumatic injury. Inj. Epidemiol. 2019;6:3. doi: 10.1186/s40621-019-0180-4.
    1. Minkowitz H.S., Rathmell J.P., Vallow S., Gargiulo K., Damaraju C.V., Hewitt D.J. Efficacy and safety of the fentanyl iontophoretic transdermal system (ITS) and intravenous patient-controlled analgesia (IV PCA) with morphine for pain management following abdominal or pelvic surgery. Pain Med. 2007;8:657–668. doi: 10.1111/j.1526-4637.2006.00257.x.
    1. Ahmad F.B., Rossen L.M., Spencer M.R., Warner M., Sutton P. Provisional Drug Overdose Death Counts. National Center for Health Statistics; Hyattsville, MD, USA: 2018.
    1. Tully A., Anderson L., Adams W., Mosier M.J. Opioid creep in burn center discharge regimens: Doubled amounts and complexity of narcotic prescriptions over seven years. Burns. 2019;45:328–334. doi: 10.1016/j.burns.2018.08.004.
    1. Baird J., Faul M., Green T.C., Howland J., Adams C.A., Jr., Hodne M.J., Bohlen N., Mello M.J. Evaluation of a Safer Opioid Prescribing Protocol (SOPP) for Patients Being Discharged From a Trauma Service. J. Trauma Nurs. 2019;26:113–120. doi: 10.1097/JTN.0000000000000435.
    1. Urman R.D., Boing E.A., Khangulov V., Fain R., Nathanson B.H., Wan G.J., Lovelace B., Pham A.T., Cirillo J. Analysis of predictors of opioid-free analgesia for management of acute post-surgical pain in the United States. Curr. Med. Res. Opin. 2019;35:283–289. doi: 10.1080/03007995.2018.1481376.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere